Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
SAN DIEGO–(BUSINESS WIRE)– Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janet Loesberg, Pharm. D., to its Board of Directors. “I am pleased to welcome Janet as the newest director to Ambrx’s Board,” … [Read more…]